Close Menu

NEW YORK – The US Food and Drug Administration on Friday granted BioFire Diagnostics' Respiratory Panel 2.1 Emergency Use Authorization.

The panel, which uses PCR and takes about 45 minutes to run, is designed to detect and differentiate between nucleic acids from SARS-CoV-2 and 20 other viral and bacterial respiratory pathogens — including various influenza A subtypes, respiratory syncytial virus, and Bordetella pertussis — in nasopharyngeal swabs from individuals suspected of having COVID-19.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.